Teva’s pipeline in 2027: Can it sustain its transformation?
While Teva is initially known for its generics business, the company is shifting its strategy to build a more innovative pipeline. The post Teva’s pipeline in 2027: Can it sustain its transformation? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is…
We haven't written up this one. Labiotech has the full story — the link below goes straight to it.
